Drug Approval | March 28, 2022
EU approves Evusheld to prevent Covid-19
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months
Vela Analytics can create concise, evidence-based in-house reports that help customers with the information to make timely, informed decisions about possible treatment options
The fund will take equity positions in India-focused healthcare and life sciences-related companies
Clinical improvements were consistent across patient subgroups including age, gender, ethnicity, and IL-36 gene mutation status
Recommendation based on Phase III PROVENT trial showing a significant reduction in the risk of developing symptomatic COVID-19, with protection lasting at least six months
Recommendation is based on pivotal data from the phase III POLARIX study
The expansion makes Exothera one of the largest viral vector facilities in Europe
The study was published recently in Genome Medicine, a leading international journal focused on translational, genomic-based medicine
This announcement comes after the formation of a new Intercontinental Region within GE Healthcare, led by Chaillot
Milltrust Ventures will also assist Oncoshot with its expansion in Australia and India, where the latter has already established partnerships amongst apex cancer institutes
Subscribe To Our Newsletter & Stay Updated
